274 related articles for article (PubMed ID: 26684817)
21. Associations between Depressive Symptomatology and Neurocognitive Impairment in HIV/AIDS.
Tymchuk S; Gomez D; Koenig N; Gill MJ; Fujiwara E; Power C
Can J Psychiatry; 2018 May; 63(5):329-336. PubMed ID: 29228820
[TBL] [Abstract][Full Text] [Related]
22. The association between oral disease and type of antiretroviral therapy among perinatally HIV-infected youth.
Shiboski CH; Yao TJ; Russell JS; Ryder MI; Van Dyke RB; Seage GR; Moscicki AB;
AIDS; 2018 Nov; 32(17):2497-2505. PubMed ID: 30096069
[TBL] [Abstract][Full Text] [Related]
23. Cognitive disorders in HIV-infected patients: are they HIV-related?
Bonnet F; Amieva H; Marquant F; Bernard C; Bruyand M; Dauchy FA; Mercié P; Greib C; Richert L; Neau D; Catheline G; Dehail P; Dabis F; Morlat P; Dartigues JF; Chêne G;
AIDS; 2013 Jan; 27(3):391-400. PubMed ID: 23079813
[TBL] [Abstract][Full Text] [Related]
24. Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada.
Robertson K; Bayon C; Molina JM; McNamara P; Resch C; Muñoz-Moreno JA; Kulasegaram R; Schewe K; Burgos-Ramirez A; De Alvaro C; Cabrero E; Guion M; Norton M; van Wyk J
AIDS Care; 2014; 26(12):1555-61. PubMed ID: 25029599
[TBL] [Abstract][Full Text] [Related]
25. Effects of HIV and combination antiretroviral therapy on cortico-striatal functional connectivity.
Ortega M; Brier MR; Ances BM
AIDS; 2015 Mar; 29(6):703-12. PubMed ID: 25849834
[TBL] [Abstract][Full Text] [Related]
26. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda.
Mutwa PR; Boer KR; Rusine JB; Muganga N; Tuyishimire D; Reiss P; Lange JM; Geelen SP
Pediatr Infect Dis J; 2013 Mar; 32(3):246-51. PubMed ID: 22976050
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.
Anderson AM; Lennox JL; Mulligan MM; Loring DW; Zetterberg H; Blennow K; Kessing C; Koneru R; Easley K; Tyor WR
J Neurovirol; 2017 Feb; 23(1):106-112. PubMed ID: 27400930
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection.
Hulgan T; Samuels DC; Bush W; Ellis RJ; Letendre SL; Heaton RK; Franklin DR; Straub P; Murdock DG; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Simpson DM; Grant I; Kallianpur AR;
Clin Infect Dis; 2015 Nov; 61(9):1476-84. PubMed ID: 26129753
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.
Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D
AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159
[TBL] [Abstract][Full Text] [Related]
31. Incidence and risk factors of herpes zoster in human immunodeficiency virus-positive patients initiating combination antiretroviral therapy in Taiwan.
Lee YC; Hung CC; Tsai MS; Zhang JY; Wu PY; Yang SP; Luo YZ; Chang HY; Liu WC; Sun HY; Chang SC
J Microbiol Immunol Infect; 2018 Feb; 51(1):38-44. PubMed ID: 27329131
[TBL] [Abstract][Full Text] [Related]
32. Short Communication: Carotid Intima-Media Thickness Is Not Associated with Neurocognitive Impairment Among People Older than 50 Years With and Without HIV Infection from Thailand.
Hiransuthikul A; Chutinet A; Sakulrak S; Samajarn J; Vongsayan P; Kijpaisalratana N; Akarathanawat W; Apornpong T; Sangarlangkarn A; Gatechompol S; Han WM; Chattranukulchai P; Kerr S; Ruxrungtham K; Avihingsanon A
AIDS Res Hum Retroviruses; 2019; 35(11-12):1170-1173. PubMed ID: 31588776
[TBL] [Abstract][Full Text] [Related]
33. Association of Brain Structure Changes and Cognitive Function With Combination Antiretroviral Therapy in HIV-Positive Individuals.
Sanford R; Fellows LK; Ances BM; Collins DL
JAMA Neurol; 2018 Jan; 75(1):72-79. PubMed ID: 29131878
[TBL] [Abstract][Full Text] [Related]
34. Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial.
Boivin MJ; Barlow-Mosha L; Chernoff MC; Laughton B; Zimmer B; Joyce C; Bwakura-Dangarembizi M; Ratswana M; Abrahams N; Fairlie L; Gous H; Kamthunzi P; McCarthy K; Familiar-Lopez I; Jean-Phillippe P; Coetzee J; Violari A; Cotton MF; Palumbo PE;
AIDS; 2018 Jan; 32(2):189-204. PubMed ID: 29112069
[TBL] [Abstract][Full Text] [Related]
35. The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.
Soeters HM; Sawry S; Moultrie H; Rie AV
J Acquir Immune Defic Syndr; 2014 Oct; 67(2):136-44. PubMed ID: 25072611
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
[TBL] [Abstract][Full Text] [Related]
37. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
Ripa M; Pogliaghi M; Chiappetta S; Nozza S; Soria A; Coppalini G; Rovelli C; Tambussi G
J Clin Virol; 2016 Dec; 85():86-89. PubMed ID: 27865174
[TBL] [Abstract][Full Text] [Related]
38. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.
Bouteloup V; Sabin C; Mocroft A; Gras L; Pantazis N; Le Moing V; d'Arminio Monforte A; Mary-Krause M; Roca B; Miro JM; Battegay M; Brockmeyer N; Berenguer J; Morlat P; Obel N; De Wit S; Fätkenheuer G; Zangerle R; Ghosn J; Pérez-Hoyos S; Campbell M; Prins M; Chêne G; Meyer L; Dorrucci M; Torti C; Thiébaut R;
HIV Med; 2017 Jan; 18(1):33-44. PubMed ID: 27625009
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatment.
Calza L; Colangeli V; Magistrelli E; Rossi N; Rosselli Del Turco E; Bussini L; Borderi M; Viale P
HIV Clin Trials; 2017 May; 18(3):110-117. PubMed ID: 28420298
[TBL] [Abstract][Full Text] [Related]
40. Effect of HIV Subtype and Antiretroviral Therapy on HIV-Associated Neurocognitive Disorder Stage in Rakai, Uganda.
Sacktor N; Saylor D; Nakigozi G; Nakasujja N; Robertson K; Grabowski MK; Kisakye A; Batte J; Mayanja R; Anok A; Gray RH; Wawer MJ
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):216-223. PubMed ID: 30865184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
